Vol. 4, Issue 1 (2015)
Effectivity of combined therapy that includes glutargine hepatoprotector in patients with comorbid permanent atrial fibrillation and liver disease on the background of longterm warfarin therapy
Atrial fibrillation (AF) is one of the most widespread rhythm disorders in the population and is considered that its frequency will continue grow because of aging of the population in the first place, and also with improving of diagnostics and treatment. So if in an age group to 55 years old it occurs in 1-1, 5% persons, so in the persons older than 80 years reaches already 10-12%. Also famous risk factors are obesity, arterial hypertension, ischemic heart disease and valvular heart diseases. A significant role given to comorbide states and among them association of AF and chronic diffuse liver diseases and fatty hepatosis in particular is not enough studied nowadays. In the same time prevalence of fatty hepatosis became an epidemic according to the experts’ assessment and is one of most frequent pathologies in clinical practice. A precise number of such patients is unknown and it is considered that it shakes in general population within 20-35% in west countries and this percent will rise without doubt. Data are collected that fatty hepatosis increases occurring of cardio-vascular diseases, especially in people with concomitant diabetes mellitus. He is also associated with early occurring as separate diastolic dysfunction of the left ventricle independent on other cardiometabolic risk factors, as well as higher frequency of hear failure development. It was also discovered a correlation between increased level of transaminases in blood, surrogate indicator of fatty hepatosis, and risk of paroxysmal AF.
How to cite this article:
Iryna Drapchak. Effectivity of combined therapy that includes glutargine hepatoprotector in patients with comorbid permanent atrial fibrillation and liver disease on the background of longterm warfarin therapy. Pharma Innovation 2015;4(1):11-16.